CLINICAL USE

Maintenance treatment of chronic obstructive pulmonary disease

DOSE IN NORMAL RENAL FUNCTION

18 micrograms once daily

PHARMACOKINETICS

  • Molecular weight                           : 472.4 (as bromide)
  • %Protein binding                           : 72
  • %Excreted unchanged in urine     : 14 (of inhaled dose)
  • Volume of distribution (L/kg)       : 32
  • half-life – normal/ESRD (hrs)      : 5–6 days/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function. Use with caution
  • <10           : Dose as in normal renal function. Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Unknown dialysability. Dose as in normal renal function. Use with caution
  • HD                     : Unknown dialysability. Dose as in normal renal function. Use with caution
  • HDF/high flux   : Unknown dialysability. Dose as in normal renal function. Use with caution
  • CAV/VVHD      : Unknown dialysability. Dose as in normal renal function. Use with caution

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs Avoid administration with other anti- cholinergic drugs

    ADMINISTRATION

    Reconstition

    –

    Route

    Inhalation

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Not to be used for acute episodes of bronchospasm .

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia